## CORRECTION Open Access



# Correction: Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study

Tomo Nozawa<sup>1\*</sup>, Naomi Iwata<sup>2</sup>, Toru Igarashi<sup>3</sup>, Ichiro Kobayashi<sup>4</sup>, Shoji Ota<sup>5</sup>, Takako Yamada<sup>5</sup>, Etsuya Bando<sup>5</sup>, Katsuyoshi Habiro<sup>5</sup> and Syuji Takei<sup>6</sup>

Correction: Pediatr Rheumatol 23, 19 (2025) https://doi.org/10.1186/s12969-025-01069-4

Following publication of the original article [1], we have been notified that the y-axis labels in Fig. 2 (b) was incorrectly displayed due to a character encoding issue during the publication process.

The original article can be found online at https://doi.org/10.1186/s12969-025-01069-4.

\*Correspondence:

Tomo Nozawa


tnozawa@yokohama-cu.ac.jp

- <sup>1</sup> Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
- $^2$  Department of Infection and Immunology, Aichi Children'S Health and Medical Center, Obu, Japan
- <sup>3</sup> Department of Pediatrics, Nippon Medical School, Tokyo, Japan
- <sup>4</sup> Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, Sapporo, Japan
- <sup>5</sup> Bristol Myers Squibb, Tokyo, Japan
- <sup>6</sup> Faculty of Medicine, School of Health Sciences, Kagoshima University, Kagoshima, Japan




© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

## Originally published figure:




		No. of patients	Probability of	
Week	At risk	discontinued oral corticosteroids	continuation of oral corticosteroids (%)	95% CI
0	35	-	-	-
4	31	2	94.29	(79.03, 98.54)
8	30	3	91.14	(74.95, 97.06)
12	25	6	81.38	(63.07, 91.20)
16	21	9	71.33	(51.99, 83.99)
20	21	9	71.33	(51.99, 83.99)
24	19	11	64.54	(45.02, 78.64)
28	18	11	64.54	(45.02, 78.64)
32	17	11	64.54	(45.02, 78.64)
36	17	11	64.54	(45.02, 78.64)
40	16	12	60.74	(41.10, 75.61)
44	15	13	56.94	(37.34, 72.48)
48	14	14	53.15	(33.72, 69.25)
52	-	-	-	(-,-)




	At the start of abatacept administration	At the end of abatacept administration
N	34	34
Mean (SD)	0.20 (0.14)	0.11 (0.16)
Minimum, Maximum	0.02, 0.53	0.00, 0.66

# Correct figure:



Week	At risk	No. of patients discontinued oral corticosteroids	Probability of continuation of oral corticosteroids (%)	95% CI
0	35	-	-	-
4	31	2	94.29	(79.03, 98.54)
8	30	3	91.14	(74.95, 97.06)
12	25	6	81.38	(63.07, 91.20)
16	21	9	71.33	(51.99, 83.99)
20	21	9	71.33	(51.99, 83.99)
24	19	11	64.54	(45.02, 78.64)
28	18	11	64.54	(45.02, 78.64)
32	17	11	64.54	(45.02, 78.64)
36	17	11	64.54	(45.02, 78.64)
40	16	12	60.74	(41.10, 75.61)
44	15	13	56.94	(37.34, 72.48)
48	14	14	53.15	(33.72, 69.25)
52	-	-	-	(-,-)



 $\hfill \blacksquare$  At the start of abatacept administration  $\hfill \blacksquare$  At the end of abatacept administration

	At the start of abatacept administration	At the end of abatacept administration
N	34	34
Mean (SD)	0.20 (0.14)	0.11 (0.16)
Minimum, Maximum	0.02, 0.53	0.00, 0.66

The original article has been corrected.

Published online: 12 March 2025

### Reference

 Nozawa, et al. Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study. Pediatr Rheumatol. 2025;23:19. https://doi.org/10. 1186/s12969-025-01069-4.